Replies to post #240815 on Amarin Corp Plc (AMRN)

[io_io]

Current case does not argue composition patents because there is no argument ... the generics would directly infringe on Vascepa composition patents...see stipulated facts. The composition patents are enough to bar launch of Vascepa composition in any indication.

Pump away, but I already addressed that to you here.